

15. (new) The method according to claim 14, wherein said at least one of an infectious disease, an inflammatory disease or a tumour disease is caused by at least one of a bacteria, a fungi, a protozoa or a virus.

16. (new) A method of treating at least one of an infectious disease, an inflammatory disease or a tumour disease, said method comprising administering a long pentraxin PTX3 in a pharmaceutically acceptable excipient to an individual in need of said treatment.--

REMARKS

Reconsideration is requested.

Claims 9-11 have been canceled above, without prejudice.

Claims 13-16 have been added. No new matter has been added. Claim 1-8 and 12-16 are pending.

The applicants elect, with traverse, the subject matter of the Examiner's Group I (i.e., claims 1-5) for further prosecution. The restriction requirement should be withdrawn as examination of all the claimed subject matter would not be an undue burden on the Examiner.

In the event the restriction requirement is not withdrawn, rejoinder is requested of at least claims 13-15, which are directed to methods of using the long pentraxin PTX3 of claim 1, with the product claims once allowable subject matter is identified. The Examiner is also requested to allow the applicants the opportunity to amend method claims to allow rejoinder, once allowable product claims are identified.


BOTTAZZI et al.
Serial No. 09/555,473

An early and favorable Action on the merits of all the claimed subject matter is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100